EBViNT cell (EBV Specific Autologous CD8+ T Cell)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for EBViNT cell (EBV Specific Autologous CD8+ T Cell), covering 2022-07-11 to 2022-07-11. Get the full timeline:
Most recent: Clinical Trial Update: A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies [Phase 1, Phase 2]